产品编号 :
Cas No. :
CAS No. |
1132827-21-4 |
|---|---|
中文名称 |
奎扎替尼二盐酸盐 |
英文名称 |
Quizartinib dihydrochloride |
别名 |
AC 010220 (dihydrochloride);AC 220 dihydrochloride;Quizartinib dihydrochloride;Quizartinib HCl;1-(5-tert-butyl-1,2-oxazol-3-yl)-3-[4-[6-(2-morpholin-4-ylethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl]urea:dihydrochloride;AC-220;AC220;Quizartinib hydrochloride;Quizartinib HCl (AC-220 |
标准英文名 |
Quizartinib hydrochloride |
MDL No. |
MFCD18633276 |
分子式 |
C29H34Cl2N6O4S |
分子量 |
633.60 |
精确分子量 |
632.17 |
SMILES |
O=C(NC1=CC=C(C2=CN3C(SC4=CC(OCCN5CCOCC5)=CC=C34)=N2)C=C1)NC6=NOC(C(C)(C)C)=C6.[H]Cl.[H]Cl |
标准SMILES |
Cl.Cl.CC(C)(C)C1=CC(NC(=O)NC2C=CC(=CC=2)C2=CN3C(=N2)SC2=CC(=CC=C32)OCCN2CCOCC2)=NO1 |
用途 |
Quizartinib dihydrochloride (also known as AC220) is a potent, orally administered FLT3 receptor tyrosine kinase inhibitor approved in Japan for the treatment of patients with relapsed or refractory FLT3-ITD-positive acute myeloid leukemia (AML). As a second-generation FLT3 inhibitor, quizartinib demonstrates improved tolerability, potency, and oral pharmacokinetic properties compared to first-generation FLT3 inhibitors. |
InChIKey |
DHYPGRVMIOATAE-UHFFFAOYSA-N |
|
|
评论 |
|---|